GB9105992D0
(en)
*
|
1991-03-21 |
1991-05-08 |
Smithkline Beecham Biolog |
Vaccine
|
EP0761231B1
(de)
*
|
1992-06-25 |
2000-01-12 |
SMITHKLINE BEECHAM BIOLOGICALS s.a. |
Adjuvantien enthaltende Impfstoffzusammensetzung
|
AU6141094A
(en)
*
|
1993-02-19 |
1994-09-14 |
Smithkline Beecham Biologicals (Sa) |
Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
|
US5773011A
(en)
*
|
1993-09-27 |
1998-06-30 |
Gerbu Biotechnik Gmbh |
Method of preparing a synergistic immunological adjuvant formulation
|
US6083513A
(en)
*
|
1993-11-16 |
2000-07-04 |
Gerbu Biotechnik Gmbh |
Method for increasing the yield of antibodies in the techniques of immunology
|
GB9326253D0
(en)
*
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
AUPM446594A0
(en)
*
|
1994-03-16 |
1994-04-14 |
Csl Limited |
Cytotoxic t-cell epitopes identified within epstein-barr virus
|
GB9506863D0
(en)
*
|
1995-04-03 |
1995-05-24 |
Smithkline Beecham Biolog |
Vaccines
|
US20010053365A1
(en)
*
|
1995-04-25 |
2001-12-20 |
Smithkline Beecham Biologicals S.A. |
Vaccines
|
UA56132C2
(uk)
*
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
US6846489B1
(en)
*
|
1995-04-25 |
2005-01-25 |
Smithkline Beecham Biologicals S.A. |
Vaccines containing a saponin and a sterol
|
GB9513261D0
(en)
*
|
1995-06-29 |
1995-09-06 |
Smithkline Beecham Biolog |
Vaccines
|
EP0909323B1
(de)
|
1996-01-04 |
2007-02-28 |
Novartis Vaccines and Diagnostics, Inc. |
Bakterioferritin aus helicobacter pylori
|
US7112331B2
(en)
|
1996-02-09 |
2006-09-26 |
Smithkline Beecham Biologicals, S.A. |
Vaccines against varicella zoster virus gene 63 product
|
GB9616351D0
(en)
*
|
1996-08-02 |
1996-09-11 |
Smithkline Beecham Biolog |
Vaccine composition
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
GB9706957D0
(en)
*
|
1997-04-05 |
1997-05-21 |
Smithkline Beecham Plc |
Formulation
|
JP4583511B2
(ja)
*
|
1997-05-20 |
2010-11-17 |
ガレニカ ファーマシューティカルズ, インコーポレイテッド |
アジュバントおよび免疫刺激活性を有するトリテルペンサポニンアナログ
|
US6080725A
(en)
*
|
1997-05-20 |
2000-06-27 |
Galenica Pharmaceuticals, Inc. |
Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
|
GB9712347D0
(en)
*
|
1997-06-14 |
1997-08-13 |
Smithkline Beecham Biolog |
Vaccine
|
US7459524B1
(en)
*
|
1997-10-02 |
2008-12-02 |
Emergent Product Development Gaithersburg Inc. |
Chlamydia protein, sequence and uses thereof
|
GB9724531D0
(en)
|
1997-11-19 |
1998-01-21 |
Smithkline Biolog |
Novel compounds
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
KR100633212B1
(ko)
|
1998-02-05 |
2006-10-11 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신접종을 위한 융합 단백질 및 조성물의 제조를 위해사용되는 mage 군으로부터의 종양 관련 항원 유도체및 이들을 암호화하고 있는 핵산 서열
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
JP4227302B2
(ja)
|
1998-04-07 |
2009-02-18 |
コリクサ コーポレイション |
Mycobacteriumtuberculosis抗原の融合タンパク質およびその使用
|
GB9808866D0
(en)
|
1998-04-24 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
BR9910005A
(pt)
*
|
1998-04-29 |
2001-01-16 |
American Cyanamid Co |
Composição de vacina, processos para imunização contra neisseria gonorrhoeae e para preparar uma composição de vacina, sequência de dna isolada e purificada, plasmìdeo, célula hospedeira, processo para produção de uma proteìna pilina recombinante quimérica de neisseria gonorrhoeae e neisseria meningitidis, proteìna pilina recombinante quimérica isolada e purificada de neisseria gonorhoeae e neisseria meningitidis, e, processo para imunização contra neisseria muningitidis
|
US6306404B1
(en)
|
1998-07-14 |
2001-10-23 |
American Cyanamid Company |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
WO2000008051A2
(en)
*
|
1998-08-07 |
2000-02-17 |
University Of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
US6262029B1
(en)
|
1998-08-14 |
2001-07-17 |
Galenica Pharmaceuticals, Inc. |
Chemically modified saponins and the use thereof as adjuvants
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
GB9820525D0
(en)
*
|
1998-09-21 |
1998-11-11 |
Allergy Therapeutics Ltd |
Formulation
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
PL201482B1
(pl)
*
|
1998-10-16 |
2009-04-30 |
Smithkline Beecham Biolog |
Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
|
GB9826886D0
(en)
*
|
1998-12-07 |
1999-01-27 |
Smithkline Beecham Biolog |
Novel compounds
|
US20020061848A1
(en)
*
|
2000-07-20 |
2002-05-23 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
BR9916020A
(pt)
|
1998-12-08 |
2002-01-22 |
Corixa Corp |
Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia
|
ES2374055T3
(es)
|
1998-12-08 |
2012-02-13 |
Glaxosmithkline Biologicals S.A. |
Nuevos compuestos derivados de neisseria meningitidis.
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
US7666988B1
(en)
|
1999-03-12 |
2010-02-23 |
Glaxosmithkline Biologicals S.A. |
BASB082 Polypeptides
|
SI1163000T1
(sl)
|
1999-03-19 |
2008-06-30 |
Glaxosmithkline Biolog Sa |
Vakcina proti antigenom iz bakterij
|
GB9909077D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
JP2002543769A
(ja)
|
1999-04-02 |
2002-12-24 |
コリクサ コーポレイション |
肺癌の治療および診断のための化合物および方法
|
PL203951B1
(pl)
|
1999-04-19 |
2009-11-30 |
Smithkline Beecham Biolog |
Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
US6635261B2
(en)
|
1999-07-13 |
2003-10-21 |
Wyeth Holdings Corporation |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
GB9918319D0
(en)
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB9919468D0
(en)
|
1999-08-17 |
1999-10-20 |
Smithkline Beecham Biolog |
Vaccine
|
EP1808180A3
(de)
|
1999-10-22 |
2010-12-22 |
Sanofi Pasteur Limited |
Modifiziertes GP 100 und Verwendung dafür
|
GB0000891D0
(en)
*
|
2000-01-14 |
2000-03-08 |
Allergy Therapeutics Ltd |
Formulation
|
MXPA02007413A
(es)
*
|
2000-01-31 |
2004-07-30 |
Smithkline Beecham Biolog |
Vacuna para la inmunizacion profilactica o terapeutica contra el vih.
|
DK1265915T3
(da)
|
2000-02-23 |
2011-02-14 |
Glaxosmithkline Biolog Sa |
Nye forbindelser
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
ES2303525T3
(es)
|
2000-04-21 |
2008-08-16 |
Corixa Corporation |
Compuestos y metodos para el tratamiento y diagnostico de infeccion por chlamydia.
|
US6919187B2
(en)
*
|
2000-04-21 |
2005-07-19 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
AU2001258102B2
(en)
|
2000-05-10 |
2007-03-01 |
Aventis Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
ES2374620T3
(es)
|
2000-06-20 |
2012-02-20 |
Corixa Corporation |
Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos.
|
EP1961819A3
(de)
|
2000-06-28 |
2008-11-12 |
Corixa Corporation |
Zusammensetzungen und Verfahren zur Heilung und Diagnose von Lungenkrebs
|
US20030180316A1
(en)
|
2000-06-29 |
2003-09-25 |
Dominique Boutriau |
Multivalent vaccine composition
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
UA79735C2
(uk)
|
2000-08-10 |
2007-07-25 |
Глаксосмітклайн Байолоджікалз С.А. |
Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
KR100831139B1
(ko)
|
2000-10-18 |
2008-05-20 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
EP1201250A1
(de)
*
|
2000-10-25 |
2002-05-02 |
SMITHKLINE BEECHAM BIOLOGICALS s.a. |
Immunogenische Zusammensetzung die hepatische Phaseantigene aus Plasmodium enthält
|
CA2425303A1
(en)
|
2000-10-27 |
2002-05-02 |
John Telford |
Nucleic acids and proteins from streptococcus groups a & b
|
US6892140B1
(en)
*
|
2000-11-27 |
2005-05-10 |
Enteron, Inc. |
Immunogenic cancer peptides and uses thereof
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
CA2430379A1
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
GB0103171D0
(en)
|
2001-02-08 |
2001-03-28 |
Smithkline Beecham Biolog |
Vaccine composition
|
EP2269639B1
(de)
|
2001-02-23 |
2018-11-28 |
GlaxoSmithKline Biologicals s.a. |
Influenza Vakzinzusammensetzungen zur intradermaler Verabreichung
|
US20030031684A1
(en)
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US20020193295A1
(en)
*
|
2001-05-04 |
2002-12-19 |
Emanuel Calenoff |
Immunogenic peptides and uses thereof
|
EP1515982A4
(de)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
|
TWI228420B
(en)
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
US20030108565A1
(en)
|
2001-07-10 |
2003-06-12 |
Johnson Mark E. |
Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
GB0118367D0
(en)
|
2001-07-27 |
2001-09-19 |
Glaxosmithkline Biolog Sa |
Novel use
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
ES2405405T3
(es)
|
2001-12-17 |
2013-05-31 |
Corixa Corporation |
Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
US7030094B2
(en)
*
|
2002-02-04 |
2006-04-18 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
|
EP2572707A3
(de)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Mikropartikel mit adsorbierten polypeptidhaltigen Molekülen
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
PL209696B1
(pl)
|
2002-04-19 |
2011-10-31 |
Univ Toronto |
Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
|
CA2489292A1
(en)
|
2002-06-13 |
2003-12-24 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
EP2316479B8
(de)
*
|
2002-07-18 |
2015-03-18 |
University of Washington |
Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
|
WO2004014419A1
(en)
|
2002-08-02 |
2004-02-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
DK2351579T3
(en)
|
2002-10-11 |
2017-01-09 |
Novartis Vaccines And Diagnostics S R L |
Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages.
|
PL376792A1
(pl)
|
2002-10-23 |
2006-01-09 |
Glaxosmithkline Biologicals S.A. |
Sposoby szczepienia przeciwko malarii
|
EP2279746B1
(de)
|
2002-11-15 |
2013-10-02 |
Novartis Vaccines and Diagnostics S.r.l. |
Oberflächenproteine in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
PT1581812E
(pt)
|
2003-01-06 |
2008-09-22 |
Wyeth Corp |
Composições e métodos para diagnóstico e tratamento de cancros do cólon
|
EP2289546A3
(de)
|
2003-01-30 |
2011-03-30 |
Novartis Vaccines and Diagnostics S.r.l. |
Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
WO2005020964A1
(en)
|
2003-06-02 |
2005-03-10 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
PL2272532T3
(pl)
|
2003-09-02 |
2016-07-29 |
Glaxosmithkline Biologicals Sa |
Szczepionka rotawirusowa
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP1670506B1
(de)
|
2003-10-02 |
2012-11-21 |
Novartis AG |
Flüssige vakzine für multiple meningokokken-serogruppen
|
DE602004028262D1
(de)
|
2003-10-02 |
2010-09-02 |
Glaxosmithkline Biolog Sa |
B. pertussis antigene und ihre verwendung bei der vakzinierung
|
GB0323965D0
(en)
*
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
AU2004308964B2
(en)
|
2003-12-23 |
2010-09-16 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of HPV and methods of their use
|
AU2005213457A1
(en)
|
2004-02-05 |
2005-08-25 |
The Ohio State University Research Foundation |
Chimeric VEGF peptides
|
US20080254065A1
(en)
|
2004-03-09 |
2008-10-16 |
Chiron Corporation |
Influenza Virus Vaccines
|
BRPI0510315A
(pt)
|
2004-04-30 |
2007-10-16 |
Chiron Srl |
integração de vacinação com conjugado meningocócico
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
GB0411411D0
(en)
*
|
2004-05-21 |
2004-06-23 |
Glaxosmithkline Biolog Sa |
Vaccines
|
US20090104226A1
(en)
|
2004-05-21 |
2009-04-23 |
Novartis Vaccines And Diagnostics Inc. |
Alphavirus Vectors for Respiratory Pathogen Vaccines
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
DE602005025342D1
(de)
|
2004-05-28 |
2011-01-27 |
Glaxosmithkline Biolog Sa |
Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
|
US20060165716A1
(en)
|
2004-07-29 |
2006-07-27 |
Telford John L |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0420634D0
(en)
*
|
2004-09-16 |
2004-10-20 |
Glaxosmithkline Biolog Sa |
Vaccines
|
ES2540770T3
(es)
|
2004-09-22 |
2015-07-13 |
Glaxosmithkline Biologicals Sa |
Composición inmunógena para uso en vacunación contra estafilococos
|
EP1797173B1
(de)
|
2004-10-08 |
2014-05-14 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Modulierung der replikationsrate durch verwendung von seltener verwendeten synonymen kodons
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
PE20061329A1
(es)
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
Anticuerpos ab humanizados para mejorar la cognicion
|
EP2433647A3
(de)
|
2005-01-27 |
2012-06-06 |
Children's Hospital & Research Center at Oakland |
Gna1870-basierte vesikelimpfstoffe für breitbandschutz gegen neisseria meningitidis-bedingte erkrankungen
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
WO2006089264A2
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
尿路病原性菌株由来の抗原
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2006104890A2
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
ES2524570T3
(es)
|
2005-04-29 |
2014-12-10 |
Glaxosmithkline Biologicals S.A. |
Procedimiento de prevención o tratamiento de infección por M. tuberculosis
|
AU2006261342B2
(en)
|
2005-06-15 |
2012-02-02 |
The Ohio State University Research Foundation |
Her-2 peptides
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
EP2305701A1
(de)
|
2005-07-01 |
2011-04-06 |
Forsyth Dental Infirmary for Children |
Assays zur Detektion von Tuberkuloseantigenen und Impfstoffe
|
EP1945247A1
(de)
|
2005-10-18 |
2008-07-23 |
Novartis Vaccines and Diagnostics, Inc. |
Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
CA2628424A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
HUE051122T2
(hu)
|
2005-11-04 |
2021-03-01 |
Seqirus Uk Ltd |
Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
|
US20090304742A1
(en)
|
2005-11-04 |
2009-12-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines with reduced amount of emulsion adjuvant
|
BRPI0618254A2
(pt)
*
|
2005-11-04 |
2011-08-23 |
Novartis Vaccines & Diagnostic |
emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
|
ES2514316T3
(es)
|
2005-11-22 |
2014-10-28 |
Novartis Vaccines And Diagnostics, Inc. |
Partículas similares a virus (VLPs) de Norovirus y Sapovirus
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CN101378778B
(zh)
|
2005-12-22 |
2013-02-06 |
葛兰素史密丝克莱恩生物有限公司 |
肺炎球菌多糖缀合物疫苗
|
US7848801B2
(en)
|
2005-12-30 |
2010-12-07 |
Tti Ellebeau, Inc. |
Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
|
EP1981905B1
(de)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia-impfstoff
|
UA92782C2
(ru)
|
2006-01-17 |
2010-12-10 |
Арне Форсгрен |
Новый поверхностный белок haemophilus influenzae (белок е; ре)
|
PT2478916T
(pt)
|
2006-01-27 |
2020-07-03 |
Seqirus Uk Ltd |
Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
|
CA2646891A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
WO2007109813A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
EP2382987A1
(de)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Lagerung von Influenza-Impfstoffen ohne Kühlung
|
KR101149687B1
(ko)
|
2006-03-30 |
2012-05-25 |
엠브렉스, 인코포레이티드 |
가금류의 예방접종 방법 및 조성물
|
EA015833B1
(ru)
|
2006-03-30 |
2011-12-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Иммуногенная композиция
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
US20100021424A1
(en)
|
2006-06-02 |
2010-01-28 |
Vincent Brichard |
Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
EP2032161B1
(de)
|
2006-06-12 |
2012-07-11 |
GlaxoSmithKline Biologicals S.A. |
L3v los impfstoffe
|
BRPI0715581A2
(pt)
|
2006-07-18 |
2013-04-24 |
Glaxosmithkline Biolog Sa |
proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
EP2054081A4
(de)
*
|
2006-08-31 |
2010-07-21 |
Baylor Res Inst |
Impfstoff gegen den jc-virus
|
NZ575273A
(en)
|
2006-09-07 |
2012-02-24 |
Glaxosmithkline Biolog Sa |
Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
|
ES2536401T3
(es)
|
2006-09-11 |
2015-05-25 |
Novartis Ag |
Fabricación de vacunas contra virus de la gripe sin usar huevos
|
EP2486938B1
(de)
|
2006-09-26 |
2018-05-09 |
Infectious Disease Research Institute |
Impfstoffzusammensetzung mit einem synthetischen Adjuvans
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
US20110045022A1
(en)
|
2006-12-06 |
2011-02-24 |
Theodore Tsai |
Vaccines including antigen from four strains of influenza virus
|
MX2009009342A
(es)
|
2007-03-02 |
2009-09-11 |
Glaxosmithkline Biolog Sa |
Metodo novedoso y composiciones.
|
CN101687027B
(zh)
|
2007-04-04 |
2015-01-28 |
传染性疾病研究院 |
包含结核分枝杆菌多肽及其融合的免疫原性组合物
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
PE20090212A1
(es)
|
2007-05-02 |
2009-03-30 |
Glaxosmithkline Biolog Sa |
Kit de vacuna para la inmunizacion primaria
|
JP2010531330A
(ja)
|
2007-06-26 |
2010-09-24 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
AU2008281384C1
(en)
*
|
2007-08-02 |
2012-08-16 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope influenza vaccines
|
CN102027003A
(zh)
|
2007-08-03 |
2011-04-20 |
哈佛大学校长及研究员协会 |
衣原体抗原
|
AR067905A1
(es)
|
2007-08-13 |
2009-10-28 |
Glaxosmithkline Biolog Sa |
Vacunas
|
US8287885B2
(en)
|
2007-09-12 |
2012-10-16 |
Novartis Ag |
GAS57 mutant antigens and GAS57 antibodies
|
EP2201131B8
(de)
|
2007-09-17 |
2014-12-10 |
MDxHealth SA |
Verbesserter methylierungsnachweis
|
EP2045263A1
(de)
|
2007-10-02 |
2009-04-08 |
Universite Libre De Bruxelles |
Identifizierung und molekulare Charakterisierung von in den Speicheldrüsen von Zecken exprimierten Speichel-Metalloproteasen
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
CA2744739A1
(en)
|
2007-12-03 |
2009-06-11 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
EP3118213A1
(de)
|
2007-12-19 |
2017-01-18 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Lösliche formen von hendra- und nipah-virus-f-glycoprotein und anwendungen davon
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ586430A
(en)
|
2007-12-21 |
2012-09-28 |
Novartis Ag |
Mutant forms of streptolysin o (slo)
|
CA2710600C
(en)
*
|
2007-12-24 |
2017-06-06 |
Id Biomedical Corporation Of Quebec |
Recombinant rsv antigens
|
CA2716212A1
(en)
|
2008-02-21 |
2009-08-27 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
EP2265640B1
(de)
|
2008-03-10 |
2015-11-04 |
Children's Hospital & Research Center at Oakland |
Chimere faktor-h-bindende proteine (fhbp), die eine heterologe b-domäne enthalten, und anwendungsverfahren
|
WO2009127666A2
(en)
*
|
2008-04-15 |
2009-10-22 |
Glaxosmithkline Biologicals S.A. |
Method and compositions
|
EP3329931B1
(de)
|
2008-04-18 |
2022-06-08 |
The General Hospital Corporation |
Immuntherapien mit selbst-zusammensetzenden vakzinen
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
CA2731194A1
(en)
*
|
2008-07-18 |
2010-01-21 |
Id Biomedical Corporation Of Quebec |
Chimeric respiratory syncytial virus polypeptide antigens
|
CA2731547C
(en)
|
2008-07-25 |
2019-04-30 |
Glaxo Group Limited |
The tuberculosis rv2386c protein, compositions and uses thereof
|
UA107180C2
(uk)
|
2008-07-25 |
2014-12-10 |
Глаксосмітклайн Байолоджікалз С.А. |
Туберкульозний білок rv1753c, композиція, що його містить, та застосування
|
KR101707569B1
(ko)
|
2008-08-01 |
2017-02-16 |
감마 백신즈 피티와이 리미티드 |
인플루엔자 백신
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
EP2349209A2
(de)
|
2008-09-26 |
2011-08-03 |
Nanobio Corporation |
Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
CA2743904A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
BRPI0922132A2
(pt)
|
2008-12-03 |
2018-10-23 |
Protea Vaccine Tech Ltd |
fragmentos glutamil trna sintetase (gts).
|
EP2376108B1
(de)
|
2008-12-09 |
2017-02-22 |
Pfizer Vaccines LLC |
Ige ch3 peptidimpstoff
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
MX2011007456A
(es)
|
2009-01-12 |
2011-08-03 |
Novartis Ag |
Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
US8460674B2
(en)
|
2009-02-07 |
2013-06-11 |
University Of Washington |
HSV-1 epitopes and methods for using same
|
CA2751379C
(en)
|
2009-02-10 |
2018-06-12 |
Novartis Ag |
Influenza vaccines with reduced amounts of squalene
|
AU2010220103A1
(en)
|
2009-03-06 |
2011-09-22 |
Novartis Ag |
Chlamydia antigens
|
CN102575284A
(zh)
|
2009-03-17 |
2012-07-11 |
MDx健康公司 |
改进的基因表达检测
|
US9044447B2
(en)
|
2009-04-03 |
2015-06-02 |
University Of Washington |
Antigenic peptide of HSV-2 and methods for using same
|
SG175092A1
(en)
|
2009-04-14 |
2011-11-28 |
Novartis Ag |
Compositions for immunising against staphylococcus aerus
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
ES2552153T3
(es)
|
2009-04-30 |
2015-11-26 |
Coley Pharmaceutical Group, Inc. |
Vacuna neumocócica y usos de la misma
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
TWI494125B
(zh)
|
2009-06-05 |
2015-08-01 |
Infectious Disease Res Inst |
合成的葡萄吡喃糖基脂質佐劑
|
EP2442826B1
(de)
|
2009-06-15 |
2015-07-08 |
National University of Singapore |
Influenzaimpfstoff, zusammensetzung und seine verwendung
|
US20100316673A1
(en)
|
2009-06-16 |
2010-12-16 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
SG176807A1
(en)
|
2009-06-24 |
2012-01-30 |
Id Biomedical Corp Quebec |
Vaccine
|
PE20121541A1
(es)
|
2009-06-24 |
2012-12-21 |
Glaxosmithkline Biolog Sa |
Antigenos de virus de sincicio respiratorio recombinantes
|
ES2662716T3
(es)
|
2009-07-07 |
2018-04-09 |
Glaxosmithkline Biologicals Sa |
Inmunógenos conservados de Escherichia coli
|
SG178026A1
(en)
|
2009-07-15 |
2012-03-29 |
Novartis Ag |
Rsv f protein compositions and methods for making same
|
ES2526996T3
(es)
|
2009-07-16 |
2015-01-19 |
Novartis Ag |
Inmunógenos desintoxicados de Escherichia coli
|
PE20120817A1
(es)
|
2009-07-30 |
2012-07-07 |
Pfizer Vaccines Llc |
Peptidos tau antigenicos y usos de los mismos
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
KR101873179B1
(ko)
*
|
2009-08-26 |
2018-06-29 |
셀렉타 바이오사이언시즈, 인크. |
T-세포 도움을 유도하는 조성물
|
NZ598458A
(en)
|
2009-08-27 |
2014-03-28 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
CA2846746A1
(en)
|
2009-09-03 |
2011-03-10 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
CN102695523A
(zh)
|
2009-09-10 |
2012-09-26 |
诺华有限公司 |
针对呼吸道疾病的组合疫苗
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
US8974799B2
(en)
|
2009-09-30 |
2015-03-10 |
Novartis Ag |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
JP5960055B2
(ja)
|
2009-10-27 |
2016-08-02 |
ノバルティス アーゲー |
改変髄膜炎菌fHBPポリペプチド
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
KR20120120185A
(ko)
|
2009-12-22 |
2012-11-01 |
셀덱스 쎄라퓨틱스, 인크. |
백신 조성물
|
EP2519265B1
(de)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
An e.coli-trägerproteine konjugierte polysaccharidimmunogene
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
US20130004530A1
(en)
|
2010-03-10 |
2013-01-03 |
Jan Poolman |
Vaccine composition
|
EP2550362B1
(de)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv-glycoproteine und rekombinante vektoren
|
MX2012011189A
(es)
|
2010-03-26 |
2013-02-07 |
Glaxosmithkline Biolog Sa |
Vacuna contra el virus e inmunodeficiencia humana.
|
EP2552942B1
(de)
|
2010-03-30 |
2017-12-27 |
Children's Hospital & Research Center at Oakland |
Faktor-h-bindende proteine (fhbp) mit geänderten eigenschaften und verwendungsverfahren dafür
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2556151A1
(de)
|
2010-04-07 |
2013-02-13 |
Novartis AG |
Verfahren zur erzeugung von virusähnlichen parvovirus-b19-partikeln
|
MX2012013713A
(es)
|
2010-05-26 |
2013-01-28 |
Selecta Biosciences Inc |
Composiciones de nanovehiculos con adyuvante no acoplado.
|
DK2575870T3
(en)
|
2010-06-04 |
2017-02-13 |
Wyeth Llc |
vaccine Formulations
|
EP2576613A1
(de)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2-peptide und impfstoffe
|
WO2011154878A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
EP3153578A1
(de)
|
2010-07-06 |
2017-04-12 |
Novartis Ag |
Immunogene zusammensetzungen aus norovirus und verfahren
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
AU2011310838B2
(en)
|
2010-09-27 |
2015-11-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
US20130280322A1
(en)
|
2010-09-27 |
2013-10-24 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
BR112013011420A2
(pt)
|
2010-11-08 |
2016-08-02 |
Infectious Disease Res Inst |
vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2646459B1
(de)
|
2010-12-02 |
2020-01-08 |
Bionor Immuno AS |
Peptidgerüstentwurf
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
WO2012092934A1
(en)
|
2011-01-06 |
2012-07-12 |
Bionor Immuno As |
Monomeric and multimeric immunogenic peptides
|
AU2012211278B2
(en)
|
2011-01-26 |
2016-11-10 |
Glaxosmithkline Biologicals Sa |
RSV immunization regimen
|
EP2667891B1
(de)
|
2011-01-27 |
2021-10-06 |
Gamma Vaccines Pty Limited |
Kombinationsimpfstoffe
|
US9303070B2
(en)
|
2011-02-22 |
2016-04-05 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
ES2716010T3
(es)
|
2011-03-29 |
2019-06-07 |
Uab Research Foundation |
Métodos y composiciones para la proteína IL-10 de citomegalovirus
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
JP6054942B2
(ja)
|
2011-04-08 |
2016-12-27 |
イミューン デザイン コーポレイション |
免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
LT2707385T
(lt)
|
2011-05-13 |
2017-12-11 |
Glaxosmithkline Biologicals Sa |
Iš anksto sulieti rsv f antigenai
|
US20130156803A1
(en)
|
2011-06-04 |
2013-06-20 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6
|
EP2691530B1
(de)
|
2011-06-10 |
2018-03-07 |
Oregon Health & Science University |
Cmv-glycoproteine und rekombinante vektoren
|
WO2012177595A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
ES2687129T3
(es)
|
2011-07-25 |
2018-10-23 |
Glaxosmithkline Biologicals Sa |
Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
|
EA201490381A1
(ru)
|
2011-07-29 |
2014-06-30 |
Селекта Байосайенсиз, Инк. |
Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl)
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
AU2012308149A1
(en)
|
2011-09-12 |
2014-03-27 |
Sheena Mary Geraldine MCCORMACK |
Methods and compositions for raising an immune response to HIV
|
EP2568289A3
(de)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
|
US9511130B2
(en)
|
2011-09-14 |
2016-12-06 |
Glaxosmithkline Biologicals Sa |
Escherichia coli vaccine combination
|
CN103917245B
(zh)
|
2011-09-14 |
2017-06-06 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备糖‑蛋白质糖缀合物的方法
|
EP3617227A3
(de)
|
2011-09-16 |
2020-06-03 |
UCB Biopharma SRL |
Neutralisierende antikörpern gegen das haupt exotoxin tcda von clostridium difficile
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
US9694063B2
(en)
|
2011-12-08 |
2017-07-04 |
Glaxosmithkline Biologicals Sa |
Clostridium difficile toxin-based vaccine
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
US11510875B2
(en)
|
2012-02-07 |
2022-11-29 |
Access To Advanced Health Institute |
Adjuvant formulations comprising TLR4 agonists and methods of using the same
|
US20150273042A1
(en)
|
2012-02-24 |
2015-10-01 |
Novartis Ag |
Pilus proteins and compositions
|
US20130236484A1
(en)
|
2012-03-08 |
2013-09-12 |
Detectogen Inc. |
Leishmaniasis antigen detection assays and vaccines
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
CN104428312A
(zh)
|
2012-04-02 |
2015-03-18 |
北卡罗来纳-查佩尔山大学 |
用于登革病毒表位的方法和组合物
|
ES2837825T3
(es)
|
2012-04-26 |
2021-07-01 |
Glaxosmithkline Biologicals Sa |
Antígenos y combinaciones de antígenos
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP2659907A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2659906A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
US9169304B2
(en)
|
2012-05-01 |
2015-10-27 |
Pfenex Inc. |
Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
|
EP2659908A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
PE20142406A1
(es)
|
2012-05-04 |
2015-01-23 |
Pfizer |
Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
|
BR112014028476A2
(pt)
|
2012-05-16 |
2017-08-01 |
Immune Design Corp |
fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
|
CN104736180A
(zh)
|
2012-05-22 |
2015-06-24 |
诺华股份有限公司 |
脑膜炎球菌血清组x偶联物
|
EP2666785A1
(de)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Auf Komplementfaktor C5a basierender Impfstoff
|
US10501499B2
(en)
|
2012-06-06 |
2019-12-10 |
Bionor Immuno As |
Peptides derived from viral proteins for use as immunogens and dosage reactants
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
BR112015002483A2
(pt)
|
2012-08-03 |
2017-11-07 |
Infectious Disease Res Inst |
composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis
|
EP2703483A1
(de)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 Peptidimpfstoff
|
US10232035B2
(en)
|
2012-09-14 |
2019-03-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes virus and use thereof in vaccines
|
RU2662970C2
(ru)
|
2012-09-18 |
2018-07-31 |
Новартис Аг |
Везикулы наружной мембраны
|
MX2015004171A
(es)
|
2012-10-02 |
2015-10-22 |
Glaxosmithkline Biolog Sa |
Conjugados de sacaridos no lineales.
|
AU2013326503B2
(en)
|
2012-10-03 |
2018-04-19 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
US9982034B2
(en)
|
2012-10-24 |
2018-05-29 |
Platelet Targeted Therapeutics, Llc |
Platelet targeted treatment
|
ES2656510T3
(es)
|
2012-11-30 |
2018-02-27 |
Glaxosmithkline Biologicals S.A. |
Antígenos de Pseudomonas y combinación de antigenos
|
ES2939307T3
(es)
|
2012-12-05 |
2023-04-20 |
Glaxosmithkline Biologicals Sa |
Composición inmunogénica
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
EA032326B1
(ru)
|
2013-04-18 |
2019-05-31 |
Иммьюн Дизайн Корп. |
Монотерапия gla для применения в лечении рака
|
WO2015132619A1
(en)
|
2013-05-15 |
2015-09-11 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
CN110734500A
(zh)
|
2013-06-26 |
2020-01-31 |
北卡罗来纳-查佩尔山大学 |
用于登革病毒疫苗的方法与组合物
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3063171B1
(de)
|
2013-11-01 |
2019-07-24 |
University Of Oslo |
Albuminvarianten und verwendungen davon
|
US9993541B2
(en)
|
2013-11-13 |
2018-06-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
US11452767B2
(en)
|
2013-11-15 |
2022-09-27 |
Oslo Universitetssykehus Hf |
CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
WO2015103104A1
(en)
|
2014-01-06 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Attenuated salmonella enterica
|
AU2015208821B2
(en)
|
2014-01-21 |
2017-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3104877B1
(de)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9-impfstoff und verfahren zur verwendung davon
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
WO2015148648A1
(en)
*
|
2014-03-25 |
2015-10-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Army |
Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
|
EP3160500B1
(de)
|
2014-06-25 |
2019-08-21 |
GlaxoSmithKline Biologicals S.A. |
Clostridium difficile immunogene zusammensetzung
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
WO2016011386A1
(en)
|
2014-07-18 |
2016-01-21 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
WO2016012385A1
(en)
|
2014-07-21 |
2016-01-28 |
Sanofi Pasteur |
Vaccine composition comprising ipv and cyclodextrins
|
JP6796057B2
(ja)
|
2014-07-23 |
2020-12-02 |
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド |
H因子結合タンパク質変異体及びその使用方法
|
EP3204039B1
(de)
|
2014-10-10 |
2022-06-08 |
The Regents Of The University Of Michigan |
Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
|
WO2016070178A1
(en)
|
2014-11-02 |
2016-05-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
|
MX2017007652A
(es)
|
2014-12-10 |
2017-10-11 |
Glaxosmithkline Biologicals Sa |
Metodo de tratamiento.
|
DK3244917T3
(da)
|
2015-01-15 |
2023-05-22 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
WO2016134300A1
(en)
|
2015-02-20 |
2016-08-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for attenuated chlamydia as vaccine and vector
|
CN107249629A
(zh)
*
|
2015-02-26 |
2017-10-13 |
生控基因疫苗股份有限公司 |
包含免疫原性蛋白质及组合佐剂并用以诱发抗原特异性t细胞反应的疫苗组合物
|
CN107530416A
(zh)
|
2015-03-05 |
2018-01-02 |
西北大学 |
非神经侵染的病毒及其用途
|
EP3270897A4
(de)
|
2015-03-20 |
2018-12-05 |
The Regents Of The University Of Michigan |
Immunogene zusammensetzungen zur verwendung als impfstoff gegen bordetella
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
US10821168B2
(en)
|
2015-03-26 |
2020-11-03 |
Gpn Vaccines Pty Ltd |
Streptococcal vaccine
|
WO2016191553A1
(en)
|
2015-05-26 |
2016-12-01 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
AU2016271857B2
(en)
|
2015-06-03 |
2020-05-28 |
Affiris Ag |
IL-23-P19 vaccines
|
AU2016281904B2
(en)
|
2015-06-26 |
2022-08-11 |
Seqirus UK Limited |
Antigenically matched influenza vaccines
|
CN107849119A
(zh)
|
2015-07-07 |
2018-03-27 |
阿费里斯股份公司 |
用于治疗和预防IgE介导的疾病的疫苗
|
NZ739007A
(en)
|
2015-07-21 |
2022-08-26 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
WO2017062246A1
(en)
|
2015-10-05 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human rota virus g9p[6] strain and use as a vaccine
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
EP3377098A1
(de)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
|
WO2017109698A1
(en)
|
2015-12-22 |
2017-06-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic formulation
|
BR112018013967A2
(pt)
|
2016-01-19 |
2019-02-05 |
Pfizer |
vacinas contra o câncer
|
WO2017137085A1
(en)
|
2016-02-11 |
2017-08-17 |
Sanofi Pasteur |
Meningitidis vaccines comprising subtilinases
|
MX2018010961A
(es)
|
2016-03-10 |
2019-03-28 |
Aperisys Inc |
Proteínas de fusión de unión a antígeno con dominios de proteína de choque térmico de 70 kilodaltons (hsp70) modificada.
|
KR20180127320A
(ko)
|
2016-03-14 |
2018-11-28 |
유니버시티에트 이 오슬로 |
변경된 FcRn 결합을 갖는 조작된 면역글로불린
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
CN109310773B
(zh)
|
2016-05-16 |
2022-04-26 |
传染病研究所 |
含有tlr激动剂的配制品和使用方法
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
CA3024313A1
(en)
|
2016-05-21 |
2017-11-30 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
AU2017273650B2
(en)
|
2016-06-01 |
2022-08-18 |
Access To Advanced Health Institute |
Nanoalum particles containing a sizing agent
|
EP3471761A2
(de)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Hla-bindende impfstoffeinheiten und verwendungen davon
|
WO2018037045A1
(en)
|
2016-08-23 |
2018-03-01 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
GB201621686D0
(en)
*
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
ES2911490T3
(es)
|
2017-01-20 |
2022-05-19 |
Pfizer |
Composiciones inmunogénicas para su uso en vacunas antineumocócicas
|
JP2020515587A
(ja)
|
2017-03-31 |
2020-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
免疫原性組成物、使用及び処置方法
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
US11583578B2
(en)
|
2017-04-28 |
2023-02-21 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery
|
CN110996994A
(zh)
|
2017-08-14 |
2020-04-10 |
葛兰素史密丝克莱恩生物有限公司 |
加强免疫应答的方法
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
EP3678699A1
(de)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Impfstoffmoleküle
|
JP7339942B2
(ja)
|
2017-09-08 |
2023-09-06 |
アクセス ツー アドバンスト ヘルス インスティチュート |
サポニンを含むリポソーム製剤および使用方法
|
BR112020004747A2
(pt)
|
2017-09-13 |
2020-09-24 |
Sanofi Pasteur |
composição imunogênica de citomegalovírus humano
|
US11566050B2
(en)
|
2017-10-18 |
2023-01-31 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for norovirus vaccines and diagnostics
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
WO2019175147A1
(en)
|
2018-03-12 |
2019-09-19 |
Janssen Vaccines & Prevention B.V. |
Vaccines against intra-abdominal infections
|
CN112638936A
(zh)
|
2018-06-12 |
2021-04-09 |
葛兰素史密丝克莱恩生物有限公司 |
腺病毒多核苷酸和多肽
|
CA3107077A1
(en)
|
2018-08-07 |
2020-02-13 |
Glaxosmithkline Biologicals Sa |
Processes and vaccines
|
WO2020039033A1
(en)
|
2018-08-23 |
2020-02-27 |
Glaxosmithkline Biologicals Sa |
Immunogenic proteins and compositions
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP7320601B2
(ja)
|
2018-09-11 |
2023-08-03 |
上▲海▼市公共▲衛▼生▲臨▼床中心 |
広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
|
EP3890775A1
(de)
|
2018-12-06 |
2021-10-13 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzungen
|
EP3893926A1
(de)
|
2018-12-12 |
2021-10-20 |
Pfizer Inc. |
Immunogene multiple hetero-antigen-polysaccharid-protein-konjugate und deren verwendung
|
EP3897846A1
(de)
|
2018-12-21 |
2021-10-27 |
GlaxoSmithKline Biologicals SA |
Verfahren zur induzierung einer immunantwort
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
WO2020178359A1
(en)
|
2019-03-05 |
2020-09-10 |
Glaxosmithkline Biologicals Sa |
Hepatitis b immunisation regimen and compositions
|
CR20210522A
(es)
|
2019-03-18 |
2021-12-17 |
Janssen Pharmaceuticals Inc |
Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
|
TWI771663B
(zh)
|
2019-03-18 |
2022-07-21 |
美商詹森藥物公司 |
E. coli O-抗原多醣生物結合物之製備方法、其組合物及其使用方法
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP3956666A1
(de)
|
2019-04-18 |
2022-02-23 |
GlaxoSmithKline Biologicals S.A. |
Antigenbindendes protein und assays
|
WO2021023691A1
(en)
|
2019-08-05 |
2021-02-11 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
EP3777884A1
(de)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzung
|
EP3799884A1
(de)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzungen
|
BR112022005615A2
(pt)
|
2019-10-02 |
2022-07-12 |
Janssen Vaccines & Prevention Bv |
Peptídeos de staphylococcus e métodos de uso
|
WO2021084429A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20230045642A1
(en)
|
2019-12-19 |
2023-02-09 |
Glaxosmithkline Biologicals Sa |
S. aureus antigens and compositions thereof
|
JP2023500749A
(ja)
|
2020-01-16 |
2023-01-10 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
FimH変異体、その組成物、及びその使用
|
AU2021211012A1
(en)
|
2020-01-24 |
2022-08-25 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
EP4103587A1
(de)
|
2020-02-14 |
2022-12-21 |
Immunor AS |
Coronavirus-impfstoff
|
IL295713A
(en)
|
2020-02-21 |
2022-10-01 |
Pfizer |
Isolation of saccharides
|
PE20230170A1
(es)
|
2020-02-23 |
2023-02-01 |
Pfizer |
Composiciones de escherichia coli y sus metodos
|
WO2022029024A1
(en)
|
2020-08-03 |
2022-02-10 |
Glaxosmithkline Biologicals Sa |
Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
|
JP2023539943A
(ja)
|
2020-09-17 |
2023-09-20 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
多価ワクチン組成物及びその使用
|
US11225508B1
(en)
|
2020-09-23 |
2022-01-18 |
The University Of North Carolina At Chapel Hill |
Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
|
EP4234585A1
(de)
|
2020-10-23 |
2023-08-30 |
Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province) |
Fusionsprotein und anwendung davon
|
PE20231934A1
(es)
|
2020-10-27 |
2023-12-01 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas
|
JP2022075575A
(ja)
|
2020-11-04 |
2022-05-18 |
ファイザー・インク |
肺炎球菌ワクチンにおける使用のための免疫原性組成物
|
CA3200968A1
(en)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
JP2024502854A
(ja)
|
2021-01-12 |
2024-01-23 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
FimH変異体、それを含む組成物、及びその使用
|
US20220226465A1
(en)
|
2021-01-18 |
2022-07-21 |
ConserV Bioscience |
Coronavirus Immunogenic Compositions, Methods and Uses Thereof
|
JP2024507828A
(ja)
|
2021-02-19 |
2024-02-21 |
サノフィ パスツール インコーポレイテッド |
B群髄膜炎菌組換えワクチン
|
EP4294433A1
(de)
|
2021-02-22 |
2023-12-27 |
GlaxoSmithKline Biologicals SA |
Immunogene zusammensetzung, verwendung und verfahren
|
AU2022251305A1
(en)
|
2021-04-01 |
2023-09-07 |
Janssen Pharmaceuticals, Inc. |
Production of e. coli o18 bioconjugates
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
BR112023023671A2
(pt)
|
2021-05-28 |
2024-02-06 |
Pfizer |
Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
|
WO2023092090A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|